DOES ONE SIZE FIT ALL? UTILITY MEASUREMENT GUIDANCE ACROSS HTAS IN THE ERA OF JOINT CLINICAL ASSESSMENT AND INTERNATIONAL REFERENCE PRICING
Author(s)
Noah Marinaro, MEng, Betsy J. Lahue, MPH, Kristen Cribbs, PhD, MPH;
Alkemi LLC, Manchester Center, VT, USA
Alkemi LLC, Manchester Center, VT, USA
OBJECTIVES: Value assessment policies and collaborations, such as EUnetHTA, JCA and MFN, highlight opportunities for methods alignment across geographies. We examined cross-jurisdictional consistency in health utility measurement recommendations across 9 HTA agencies: ICER (US), CADTH (Canada), NICE (UK), HAS (France), IQWiG (Germany), AIFA/AGENAS (Italy), AEMPS (Spain), CONITEC (Brazil), and C2H (Japan).
METHODS: Utility-relevant guidance documents were identified via HTA websites and literature searches (2015-2025). Final English or translated guidance covering utility measurement for economic evaluations were included. Extracted data included required or preferred utility measures, acceptance of alternatives, country-specific value sets, mapping policies, pediatric/caregiver guidance, and references to other HTA frameworks. Descriptive analyses were conducted.
RESULTS: Fourteen guidance documents were identified across the 9 agencies, with 57% published or updated after 2022. Only HAS mandates use of a specific adult utility instrument (EQ-5D-5L). All other agencies prefer EQ-5D but do not mandate a version, with stated preferences varying (UK: EQ-5D-3L; France/Japan: EQ-5D-5L). All agencies accept alternative measures, including HUI, SF-6D, and disease-specific preference-based measures, when appropriately justified. Mapping from disease-specific or non-preference-based instruments to generic preference-based measures is permitted by 8/9 agencies, while IQWiG discourages mapping. Population-specific considerations were referenced in 6/9 agencies, most often caregiver guidance; pediatric-specific guidance was identified in 3/9, most commonly recommending EQ-5D-Y (Brazil specifies EQ-5D-Y-3L with local value sets). Country-specific value sets are required across all agencies. ICER and CADTH reference international HTA methods (including NICE) while maintaining internal guidance.
CONCLUSIONS: Utility measurement guidance is increasingly available across HTAs, but cross-jurisdiction usability remains uneven. Broad preference for EQ-5D and acceptance of alternatives supports partial harmonization, while variation in instrument versions, mapping acceptability, and pediatric/caregiver recommendations highlight opportunities to strengthen methodological alignment.
METHODS: Utility-relevant guidance documents were identified via HTA websites and literature searches (2015-2025). Final English or translated guidance covering utility measurement for economic evaluations were included. Extracted data included required or preferred utility measures, acceptance of alternatives, country-specific value sets, mapping policies, pediatric/caregiver guidance, and references to other HTA frameworks. Descriptive analyses were conducted.
RESULTS: Fourteen guidance documents were identified across the 9 agencies, with 57% published or updated after 2022. Only HAS mandates use of a specific adult utility instrument (EQ-5D-5L). All other agencies prefer EQ-5D but do not mandate a version, with stated preferences varying (UK: EQ-5D-3L; France/Japan: EQ-5D-5L). All agencies accept alternative measures, including HUI, SF-6D, and disease-specific preference-based measures, when appropriately justified. Mapping from disease-specific or non-preference-based instruments to generic preference-based measures is permitted by 8/9 agencies, while IQWiG discourages mapping. Population-specific considerations were referenced in 6/9 agencies, most often caregiver guidance; pediatric-specific guidance was identified in 3/9, most commonly recommending EQ-5D-Y (Brazil specifies EQ-5D-Y-3L with local value sets). Country-specific value sets are required across all agencies. ICER and CADTH reference international HTA methods (including NICE) while maintaining internal guidance.
CONCLUSIONS: Utility measurement guidance is increasingly available across HTAs, but cross-jurisdiction usability remains uneven. Broad preference for EQ-5D and acceptance of alternatives supports partial harmonization, while variation in instrument versions, mapping acceptability, and pediatric/caregiver recommendations highlight opportunities to strengthen methodological alignment.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HTA17
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas